Hyperphosphatemia Drugs Market by Product Type, Distribution Channel, End User 2023-2028 - PowerPoint PPT Presentation

About This Presentation
Title:

Hyperphosphatemia Drugs Market by Product Type, Distribution Channel, End User 2023-2028

Description:

According to the latest research report by IMARC Group, The global hyperphosphatemia drugs market size reached US$ 3.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 6.1 Billion by 2028, exhibiting a growth rate (CAGR) of 8.1% during 2023-2028. More Info:- – PowerPoint PPT presentation

Number of Views:0
Slides: 13
Provided by: MarcelMikaelson
Category:
Tags:

less

Transcript and Presenter's Notes

Title: Hyperphosphatemia Drugs Market by Product Type, Distribution Channel, End User 2023-2028


1
Global Hyperphosphatemia Drugs Market Research
and Forecast Report 2023-2028
  • Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group
  • International Market Analysis Research and
    Consulting Group is a leading adviser on
    management strategy and market research
    worldwide. We partner with clients in all regions
    and industry verticals to identify their
    highest-value opportunities, address their most
    critical challenges, and transform their
    businesses.
  • IMARCs information products include major
    market, scientific, economic and technological
    developments for business leaders in
    pharmaceutical, industrial, and high technology
    organizations. Market forecasts and industry
    analysis for biotechnology, advanced materials,
    chemicals, food and beverage, travel and tourism,
    nanotechnology and novel processing methods are
    at the top of the companys expertise.
  • IMARCs tailored approach combines unfathomable
    insight into the dynamics of companies and
    markets with close cooperation at all levels of
    the client organization. This ensures that our
    clients achieve unmatchable competitive
    advantage, build more proficient organizations,
    and secure lasting results.

3
Report Highlight and Description
  • According to the latest report by IMARC Group,
    titled "Hyperphosphatemia Drugs Market Global
    Industry Trends, Share, Size, Growth, Opportunity
    and Forecast 2023-2028," the global
    hyperphosphatemia drugs market size reached US
    3.8 Billion in 2022.
  • Hyperphosphatemia drugs are medications used to
    treat a medical condition called
    hyperphosphatemia, characterized by abnormally
    high levels of phosphate in the blood. Phosphate
    is an essential mineral that plays a crucial role
    in numerous physiological processes, such as bone
    formation, nerve function, and energy metabolism.
  • These drugs work by reducing the absorption of
    phosphate from the gastrointestinal tract or
    promoting its elimination through the kidneys.
    One common class of drugs used for this purpose
    is phosphate binders. These medications bind to
    dietary phosphate in the digestive tract,
    preventing its absorption into the bloodstream.
  • Request for a PDF sample of this report
    https//www.imarcgroup.com/hyperphosphatemia-drugs
    -market/requestsample

4
Report Description
  • Global Hyperphosphatemia Drugs Market Trends
  • The increasing prevalence of chronic kidney
    disease (CKD) and end-stage renal disease (ESRD)
    is driving the global market. As the incidence of
    CKD and ESRD rises globally, so does the demand
    for drugs that can effectively manage and lower
    phosphate levels in the blood. Moreover, the
    growing aging population is contributing to the
    expansion of the hyperphosphatemia drugs market.
    Elderly individuals are more susceptible to
    kidney-related conditions, leading to a higher
    prevalence of hyperphosphatemia in this
    demographic. Additionally, continual advancements
    in medical research and drug development have led
    to the introduction of new and improved
    hyperphosphatemia drugs.
  • Pharmaceutical companies are investing in
    research to develop novel medications that can
    provide better efficacy and fewer side effects,
    enhancing patient outcomes and driving market
    growth. Furthermore, the increasing awareness and
    diagnosis of hyperphosphatemia in patients with
    CKD and ESRD have also contributed to market
    expansion. Early detection and intervention are
    essential for managing the condition effectively,
    leading to a greater demand for appropriate
    pharmaceutical treatments.
  • Looking forward, the market value is projected to
    reach US 6.1 Billion by 2028, expanding at a
    CAGR of 8.1 during 2023-2028.
  • View Report TOC, Figures and Tables
    https//www.imarcgroup.com/hyperphosphatemia-drugs
    -market

5
Report Segmentation
  • Product Insights
  • Sevelamer
  • Calcium Based Phosphate Binders
  • Iron Based Phosphate Binders
  • Lanthanum Carbonate
  • Others
  •  
  • Dosage Form Insights
  • Tablets
  • Syrups
  • Capsules
  • Distribution Channel Insights
  • Hospital Pharmacies
  • Retail Pharmacies

6
Report Segmentation
  • Online Pharmacies
  • Regional Insights
  • North America
  • Asia-Pacific
  • Europe
  • Latin America
  • Middle East and Africa

7
Competitive Landscape with Key Players
  • Ardelyx Inc.
  • Fresenius Medical Care AG Co. KGaA
  • Lupin Pharmaceuticals Inc (Lupin Limited)
  • Torii Pharmaceutical Co. Ltd. (Japan Tobacco
    Inc.)
  • Vifor Pharma Management Ltd. (CSL Limited)

8
Key Questions Answered in the Report
9
Table of Contents
  • 1    Preface2    Scope and Methodology    2.1  
     Objectives of the Study    2.2  
     Stakeholders    2.3    Data Sources       
    2.3.1    Primary Sources        2.3.2  
     Secondary Sources    2.4    Market Estimation 
          2.4.1    Bottom-Up Approach        2.4.2  
     Top-Down Approach    2.5    Forecasting
    Methodology3    Executive Summary4  
     Introduction    4.1    Overview    4.2    Key
    Industry Trends5    Global Hyperphosphatemia
    Drugs Market    5.1    Market Overview    5.2  
     Market Performance    5.3    Impact of
    COVID-19  5.4    Market Forecast
  • 6     Market Breakup by Product    6.1   
    Sevelamer        6.1.1 Market Trends       
    6.1.2 Market Forecast    6.2    Calcium Based
    Phosphate Binders        6.2.1 Market Trends   
        6.2.2 Market Forecast    6.3    Iron Based
    Phosphate Binders        6.3.1 Market Trends   
        6.3.2 Market Forecast       

10
Table of Contents
  •     6.4    Lanthanum Carbonate        6.4.1
    Market Trends        6.4.2 Market Forecast   
    6.5    Others        6.5.1 Market Trends       
    6.5.2 Market Forecast7    Market Breakup by
    Dosage Form    7.1    Tablets        7.1.1
    Market Trends        7.1.2 Market Forecast   
    7.2    Syrups        7.2.1 Market Trends       
    7.2.2 Market Forecast    7.3    Capsules       
    7.3.1 Market Trends        7.3.2 Market
    Forecast8    Market Breakup by Distribution
    Channel    8.1    Hospital Pharmacies       
    8.1.1 Market Trends        8.1.2 Market
    Forecast    8.2    Retail Pharmacies       
    8.2.1 Market Trends        8.2.2 Market
    Forecast    8.3    Online Pharmacies       
    8.3.1 Market Trends        8.3.2 Market
    Forecast
  • For more information, visit https//www.imarcgrou
    p.com/hyperphosphatemia-drugs-market/toc

11
Disclaimer
  • 2023 IMARC All Rights Reserved
  • This Publication and all its contents unless
    otherwise mentioned are copyrighted in the name
    of International Market Analysis Research and
    Consulting (IMARC). No part of this publication
    may be reproduced, repackaged, redistributed or
    resold in whole or in any part. The publication
    may also not be used in any form or by and means
    graphic electronic or mechanical, including
    photocopying, recording, taping or by information
    storage or retrieval, or by any other form,
    without the express consent of International
    Market Analysis Research and Consulting (IMARC).
  • Disclaimer All contents and data of this
    publication, including forecasts, data analysis
    and opinion have been based on information and
    sources believed to be accurate and reliable at
    the time of publishing. International Market
    Analysis Research and Consulting makes no
    representation of warranty of any kind as to the
    accuracy or completeness of any Information
    provided. IMARC accepts no liability whatsoever
    for any loss or damage resulting from opinion,
    errors or inaccuracies if any found this
    publication.
  • IMARC, IMARC Group and Global Therapy Insight
    Series are registered trademarks of International
    Market Analysis Research and Consulting. All
    other trademarks used in this publication are
    registered trademarks of their respective
    companies.

12
Contact Us
Visit us at
https//www.imarcgroup.com
TELEPHONE 1-631-791-1145 E-MAIL
sales_at_imarcgroup.com
Write a Comment
User Comments (0)
About PowerShow.com